» Articles » PMID: 36241613

The Fab Region of IgG Impairs the Internalization Pathway of FcRn Upon Fc Engagement

Abstract

Binding to the neonatal Fc receptor (FcRn) extends serum half-life of IgG, and antagonizing this interaction is a promising therapeutic approach in IgG-mediated autoimmune diseases. Fc-MST-HN, designed for enhanced FcRn binding capacity, has not been evaluated in the context of a full-length antibody, and the structural properties of the attached Fab regions might affect the FcRn-mediated intracellular trafficking pathway. Here we present a comprehensive comparative analysis of the IgG salvage pathway between two full-size IgG1 variants, containing wild type and MST-HN Fc fragments, and their Fc-only counterparts. We find no evidence of Fab-regions affecting FcRn binding in cell-free assays, however, cellular assays show impaired binding of full-size IgG to FcRn, which translates into improved intracellular FcRn occupancy and intracellular accumulation of Fc-MST-HN compared to full size IgG1-MST-HN. The crystal structure of Fc-MST-HN in complex with FcRn provides a plausible explanation why the Fab disrupts the interaction only in the context of membrane-associated FcRn. Importantly, we find that Fc-MST-HN outperforms full-size IgG1-MST-HN in reducing IgG levels in cynomolgus monkeys. Collectively, our findings identify the cellular membrane context as a critical factor in FcRn biology and therapeutic targeting.

Citing Articles

SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials.

Cai Q, Guo R, Chen D, Deng Z, Gao J J Nanobiotechnology. 2025; 23(1):178.

PMID: 40050980 PMC: 11884119. DOI: 10.1186/s12951-025-03254-9.


Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties.

Seth N, Xu R, DuPrie M, Choudhury A, Sihapong S, Tyler S MAbs. 2025; 17(1):2461191.

PMID: 39936406 PMC: 11834464. DOI: 10.1080/19420862.2025.2461191.


Binding to the neonatal Fc receptor enhances the pathogenicity of anti-desmoglein-3 antibodies in keratinocytes.

Zakrzewicz A, Vanderheyden K, Galaly Y, Feldhoff S, Sips M, Brinkhaus M Front Immunol. 2024; 15:1473637.

PMID: 39450168 PMC: 11499148. DOI: 10.3389/fimmu.2024.1473637.


Selective IgG binding to the LPS glycolipid core found in bovine colostrum, or milk, during mastitis influences endotoxin function.

Hurst S, Flossdorf D, Koralagamage Don R, Pernthaner A Innate Immun. 2024; 30(5):96-118.

PMID: 39252173 PMC: 11418599. DOI: 10.1177/17534259241269724.


evaluation of the role of Fab glycosylation in cetuximab antibody dynamics.

Saporiti S, Bianchi D, Ben Mariem O, Rossi M, Guerrini U, Eberini I Front Immunol. 2024; 15:1429600.

PMID: 39185413 PMC: 11342397. DOI: 10.3389/fimmu.2024.1429600.


References
1.
Winn M, Ballard C, Cowtan K, Dodson E, Emsley P, Evans P . Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):235-42. PMC: 3069738. DOI: 10.1107/S0907444910045749. View

2.
MARTIN W, West Jr A, Gan L, Bjorkman P . Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001; 7(4):867-77. DOI: 10.1016/s1097-2765(01)00230-1. View

3.
Newland A, Sanchez-Gonzalez B, Rejto L, Egyed M, Romanyuk N, Godar M . Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2019; 95(2):178-187. PMC: 7004056. DOI: 10.1002/ajh.25680. View

4.
Simister N, Story C, Chen H, Hunt J . An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol. 1996; 26(7):1527-31. DOI: 10.1002/eji.1830260718. View

5.
Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T . Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010; 184(4):1968-76. DOI: 10.4049/jimmunol.0903296. View